2020 American Transplant Congress
Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model
*Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…2020 American Transplant Congress
Less Bleeding Associated with Apixaban versus Other Direct Acting Oral Anticoagulation in Solid Organ Transplant Recipients
*Purpose: Owing to their fixed dosing and favorable drug interaction profiles, direct acting oral anticoagulants (DOACs) have supplanted warfarin as the standard of care for…2020 American Transplant Congress
A Single Centre Experience of Conversion from Immediate Release Tacrolimus (IR-tac) to Extended Release Envarsus
*Purpose: IR-Tac is first line maintenance immunosuppression in kidney transplant recipients. Its rapid absorption of 1-2 hours can lead to peak levels (Tmax ) within…2020 American Transplant Congress
Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients
*Purpose: It is well described that there is interpatient variability in tacrolimus dose requirements among transplant recipients. CYP3A5 plays a role in this variability. Black…2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…2020 American Transplant Congress
Late Intra-Patient Tacrolimus Variability Predicts De Novo Donor-Specific Antibody and Graft Loss
*Purpose: Intra-patient variability (IPV) of tacrolimus level has been associated with poor outcomes after kidney transplantation. However, these findings were limited mainly to measurements early…2020 American Transplant Congress
Dosing and Outcomes of Conversion to Extended-Release Tacrolimus in Heart and Lung Transplant Recipients
*Purpose: Extended release tacrolimus (LCP-Tac) is a novel once daily formulation with improved pharmacokinetic parameters compared to immediate release tacrolimus (IR-Tac). LCP-Tac use in renal…2020 American Transplant Congress
De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients
University of Virginia Health System, Charlottesville, VA
*Purpose: Due to ongoing national drug shortages, our center transitioned to de novo use of LCP-tacrolimus (LCPT) in kidney transplant patients using a conservative dosing…2019 American Transplant Congress
Neutralization of Interlukin-6 by ALD518-P18 (Murine Clazakizumab) Attenuates Donor Specific Antibody Responses in a Mouse Model of Allogeneic Sensitization: A Report of Dosage Finding Study
Cedars-Sinai Med Ctr, Los Angeles, CA
*Purpose: Interleukin-6 (IL-6) is a proinflammatory cytokine involved in mediating both T-cell and B-cell responses in allograft rejection. In previous studies, we demonstrated that inhibition…2019 American Transplant Congress
Oral Ribavirin Therapy for Respiratory Syncytial Virus (RSV) in Lung Transplant Recipients: The Impact of Policy Implementation on Cost and Appropriate Use
Henry Ford Hospital, Detroit, MI
*Purpose: RSV is a leading cause of viral infections in lung transplant recipients and is associated with significant morbidity and mortality. While the role of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »